Open-Label, Uncontrolled, Single Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ≥ 29 Weeks Gestational Age to < 18 Years
Latest Information Update: 20 Apr 2025
At a glance
- Drugs Cilgavimab/tixagevimab (Primary) ; Cilgavimab/tixagevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms TRUST
- Sponsors AstraZeneca; AstraZeneca AB
Most Recent Events
- 13 May 2024 Status changed from active, no longer recruiting to completed.
- 21 Dec 2023 Planned End Date changed from 28 Jun 2024 to 29 Mar 2024.
- 21 Dec 2023 Planned primary completion date changed from 28 Jun 2024 to 29 Mar 2024.